Novel Combination Strategies in CLL
Jacqueline C. Barrientos, MD, MS, discusses exciting novel combination strategies that are being presented at the 2019 ASH Annual meeting.
Using Acalabrutinib in CLL Patients With Ibrutinib Intolerance
Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.